Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?

Affiliations

• ¹ Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York bodeil@mskcc.org.
• ² Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.
• ³ Erasmus MC and Erasmus MC Cancer Center, ENETS Center of Excellence Rotterdam, Rotterdam, The Netherlands.
• ⁴ Endocrinology Unit, IRCCS Ospedale Policlinico San Martino, and Department of Internal Medicine and Medical Specialties, University of Genova, Genova, Italy.
• ⁵ Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
• ⁶ Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
• ⁷ Nuclear Medicine Department, Medical University of Warsaw, Warsaw, Poland.
• ⁸ Department of Medicine 1, Endocrinology, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen and Nürnberg, Germany.
• ⁹ Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
• ¹⁰ Institute for Developmental Cancer Therapeutics, West German Cancer Center, University Hospital Essen, Essen, Germany.
• ¹¹ Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida.
• ¹² Institute for Virology, University Hospital Essen, Essen, Germany; and.
• ¹³ Department of Nuclear Medicine, University Hospital Essen, Essen, Germany, and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California.